| The role of calpain in oncotic cell death X Liu, T Van Vleet, RG Schnellmann Annu. Rev. Pharmacol. Toxicol. 44, 349-370, 2004 | 290 | 2004 |
| Comparison of RNA-Seq and microarray gene expression platforms for the toxicogenomic evaluation of liver from short-term rat toxicity studies MS Rao, TR Van Vleet, R Ciurlionis, WR Buck, SW Mittelstadt, ... Frontiers in genetics 9, 636, 2019 | 231 | 2019 |
| Calpain 10: a mitochondrial calpain and its role in calcium-induced mitochondrial dysfunction DD Arrington, TR Van Vleet, RG Schnellmann American Journal of Physiology-Cell Physiology 291 (6), C1159-C1171, 2006 | 213 | 2006 |
| Toxic nephropathy: environmental chemicals TR Van Vleet, RG Schnellmann Seminars in nephrology 23 (5), 500-508, 2003 | 189 | 2003 |
| An overview of machine learning and big data for drug toxicity evaluation AH Vo, TR Van Vleet, RR Gupta, MJ Liguori, MS Rao Chemical research in toxicology 33 (1), 20-37, 2019 | 132 | 2019 |
| Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates PK Mahalingaiah, R Ciurlionis, KR Durbin, RL Yeager, BK Philip, B Bawa, ... Pharmacology & Therapeutics 200, 110-125, 2019 | 113 | 2019 |
| Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPARα/γ agonist: evidence for urolithiasis as the inciting event in the mode of action MA Dominick, MR White, TP Sanderson, T Van Vleet, SM Cohen, ... Toxicologic Pathology 34 (7), 903-920, 2006 | 108 | 2006 |
| Liver microphysiological systems development guidelines for safety risk assessment in the pharmaceutical industry AR Baudy, MA Otieno, P Hewitt, J Gan, A Roth, D Keller, R Sura, ... Lab on a Chip 20 (2), 215-225, 2020 | 100 | 2020 |
| Navigating tissue chips from development to dissemination: A pharmaceutical industry perspective L Ewart, K Fabre, A Chakilam, Y Dragan, DB Duignan, J Eswaraka, J Gan, ... Experimental Biology and Medicine 242 (16), 1579-1585, 2017 | 81 | 2017 |
| Introduction to a manuscript series on the characterization and use of microphysiological systems (MPS) in pharmaceutical safety and ADME applications K Fabre, B Berridge, WR Proctor, S Ralston, Y Will, SW Baran, G Yoder, ... Lab on a Chip 20 (6), 1049-1057, 2020 | 79 | 2020 |
| Biochemical factors underlying the age-related sensitivity of turkeys to aflatoxin B1 PJ Klein, TR Van Vleet, JO Hall, RA Coulombe Jr Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology …, 2002 | 78 | 2002 |
| Novel computational approach to predict off-target interactions for small molecules MS Rao, R Gupta, MJ Liguori, M Hu, X Huang, SR Mantena, ... Frontiers in big data 2, 25, 2019 | 74 | 2019 |
| Potential functional and pathological side effects related to off-target pharmacological activity JJ Lynch III, TR Van Vleet, SW Mittelstadt, EAG Blomme Journal of pharmacological and toxicological methods 87, 108-126, 2017 | 70 | 2017 |
| Aflatoxin B1 Alters the Expression of p53 in Cytochrome P450-Expressing Human Lung Cells TR Van Vleet, TL Watterson, PJ Klein, RA Coulombe Jr Toxicological Sciences 89 (2), 399-407, 2006 | 65 | 2006 |
| Inhibition of Human Cytochrome P450 2E1 by Nicotine, Cotinine, and Aqueous Cigarette Tar Extract in Vitro TR Van Vleet, DW Bombick, RA Coulombe Jr Toxicological Sciences 64 (2), 185-191, 2001 | 65 | 2001 |
| Effects of dietary butylated hydroxytoluene on aflatoxin B1-relevant metabolic enzymes in turkeys PJ Klein, TR Van Vleet, JO Hall, RA Coulombe Jr Food and chemical toxicology 41 (5), 671-678, 2003 | 61 | 2003 |
| Comparative Aflatoxin B1 Activation and Cytotoxicity in Human Bronchial Cells Expressing Cytochromes P450 1A2 and 3A4 TR Van Vleet, K Macé, RA Coulombe Jr Cancer research 62 (1), 105-112, 2002 | 61 | 2002 |
| Acyl glucuronide metabolites: Implications for drug safety assessment TR Van Vleet, H Liu, A Lee, EAG Blomme Toxicology letters 272, 1-7, 2017 | 59 | 2017 |
| Dietary butylated hydroxytoluene protects against aflatoxicosis in turkeys PJ Klein, TR Van Vleet, JO Hall, RA Coulombe Jr Toxicology and applied pharmacology 182 (1), 11-19, 2002 | 49 | 2002 |
| Screening strategies and methods for better off-target liability prediction and identification of small-molecule pharmaceuticals TR Van Vleet, MJ Liguori, JJ Lynch III, M Rao, S Warder SLAS DISCOVERY: Advancing Life Sciences R&D 24 (1), 1-24, 2019 | 39 | 2019 |
Rick SchnellmannArizona在 email.arizona.edu 的电子邮件经过验证
